Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIT-CD: Thromboprophylaxis in Cushing's Disease
NCT04486859Active, not recruiting
- Sponsor
- Huashan Hospital
- Start
- Dec 2020
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rivaroxaban in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by Huashan Hospital. Primary endpoint: VTE incidence rate at 12 weeks. Started Dec 2020; status: active, not recruiting.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT04486859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04486859.